Drug Trial Radar · NCT05362045
A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Nov 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
158
Actual
Start
May 16, 2022
Primary completion
Aug 19, 2022
Study completion Aug 19, 2022
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effects on the single-dose drug levels of mavacamten in healthy participants.
Conditions
- Healthy Participants
Interventions
MavacamtenDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to approximately 1 month
- Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration ((AUC(0-T))Time frame: Up to approximately 1 month
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time ((AUC(INF))Time frame: Up to approximately 1 month
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Clinical pharmacology of Miami
Miami, Florida
Advanced Pharma CR, LLC
Miami, Florida
QPS Springfield
Springfield, Missouri
Ppd Phase I Clinic
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.